Prostate Cancer
A Phase II, randomized, open-label, multi-center study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive prostate cancer (mHSPC) (CJSB462C12201)
- Details
ClinicalTrials.gov ID:
NCT06991556
Diagnosis Type:
NA
USOR Number:
- Address
,
P: